APG 5918
Alternative Names: APG-5918; EEDi-5273Latest Information Update: 14 May 2025
At a glance
- Originator University of Michigan
- Developer Ascentage Pharma
- Class Antianaemics; Antineoplastics; Small molecules
- Mechanism of Action Polycomb repressive complex 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Anaemia; Haematological malignancies; Solid tumours
- Preclinical Haemoglobinopathies
Most Recent Events
- 28 Apr 2025 Pharmacodynamics data from a preclinical study in Prostate cancer released by Ascentage Pharma
- 07 Dec 2024 Safety, pharmacokinetics and pharmacodynamics data from a preclinical studies in Haematological malignancies presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
- 13 Jun 2024 Pharmacodynamics data from a preclinical study in Anaemia presented at the 29th Congress of the European Haematology Association (EHA-2024)